HomeCompareIPSEF vs DIVO

IPSEF vs DIVO: Dividend Comparison 2026

IPSEF yields 1.45% · DIVO yields 6.62%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 IPSEF wins by $10.2K in total portfolio value· pulled ahead in Year 8
10 years
IPSEF
IPSEF
● Live price
1.45%
Share price
$113.13
Annual div
$1.64
5Y div CAGR
38.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$41.2K
Annual income
$6,651.20
Full IPSEF calculator →
DIVO
DIVO
● Live price
6.62%
Share price
$44.00
Annual div
$2.91
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$31.0K
Annual income
$1,008.47
Full DIVO calculator →

Portfolio growth — IPSEF vs DIVO

📍 IPSEF pulled ahead of the other in Year 8

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodIPSEFDIVO
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, IPSEF + DIVO cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
IPSEF pays
DIVO pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

IPSEF
Annual income on $10K today (after 15% tax)
$123.06/yr
After 10yr DRIP, annual income (after tax)
$5,653.52/yr
DIVO
Annual income on $10K today (after 15% tax)
$562.67/yr
After 10yr DRIP, annual income (after tax)
$857.20/yr
At 15% tax rate, IPSEF beats the other by $4,796.32/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of IPSEF + DIVO for your $10,000?

IPSEF: 50%DIVO: 50%
100% DIVO50/50100% IPSEF
Portfolio after 10yr
$36.1K
Annual income
$3,829.84/yr
Blended yield
10.61%
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

IPSEF buys
0
DIVO buys
0
No recent congressional trades found for IPSEF or DIVO in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricIPSEFDIVO
Forward yield1.45%6.62%
Annual dividend / share$1.64$2.91
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR38.6%0%
Portfolio after 10y$41.2K$31.0K
Annual income after 10y$6,651.20$1,008.47
Total dividends collected$18.8K$8.4K
Payment frequencyquarterlyquarterly
SectorStockETF

Year-by-year: IPSEF vs DIVO ($10,000, DRIP)

YearIPSEF PortfolioIPSEF Income/yrDIVO PortfolioDIVO Income/yrGap
1$10,901$200.65$11,362$661.96$461.00DIVO
2$11,947$283.32$12,860$702.91$913.00DIVO
3$13,186$402.22$14,504$743.56$1.3KDIVO
4$14,684$575.02$16,303$783.73$1.6KDIVO
5$16,541$829.46$18,268$823.31$1.7KDIVO
6$18,909$1,210.33$20,408$862.17$1.5KDIVO
7$22,025$1,792.24$22,737$900.20$712.00DIVO
8← crossover$26,271$2,704.08$25,266$937.31+$1.0KIPSEF
9$32,288$4,177.89$28,008$973.42+$4.3KIPSEF
10$41,199$6,651.20$30,977$1,008.47+$10.2KIPSEF

IPSEF vs DIVO: Complete Analysis 2026

IPSEFStock

Ipsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, gastroenterology, cognitive disorders, and rare diseases. It offers Somatuline for neuroendocrine tumors and acromegaly; Decapeptyl for the treatment of advanced metastatic prostate cancer; Cabometyx for renal cell and second-line hepatocellular carcinoma; Onivyde for second-line metastatic pancreatic cancer; Dysport for motor muscular disorders and medical aesthetics; NutropinAq for growth failure in children due to growth hormone (GH) deficiency, turner syndrome, chronic renal failure, and GH deficiency in adults; and Increlex for growth failure in children and adolescents. The company also offers Smecta for chronic and acute diarrhea, and pain associated with functional bowel diseases; Forlax for constipation; Fortrans/Eziclen for bowel cleansing prior to endoscopy, X-ray examination, and colonic surgery; and Tanakan for cognitive disorders in adults, vertigo of vestibular origin and vestibular rehabilitation, and tinnitus. In addition, it provides Xermelo for the carcinoid syndrome; Cometriq for medullary thyroid cancer; Smebiocta/SmectaFlora Protect, a food supplement; SmectaGas, a medical device used in the symptomatic treatment of gas-related gastrointestinal disorders and relief of gas-related symptoms; and Etiasa for inflammatory bowel diseases. Further, the company offers other consumer healthcare products in the gastro-intestinal area, including Buscopan, Clin4000, Prontalgine, Suppositoria Glycerini, Mucothiol, Floractin, and Mucodyne. Ipsen S.A. has agreements with Debiopharm; Exelixis; Galderma; Blueprint Medicines; TerSera Therapeutics; Rhythm Pharmaceuticals; Teijin; Braintree Laboratories; Ethypharm; Schwabe; BAKX Therapeutics Inc.; and Exicure. The company was founded in 1929 and is headquartered in Boulogne-Billancourt, France.

Full IPSEF Calculator →

DIVOETF

DIVO is an ETF of high-quality large cap companies with a history of dividend and earnings growth, along with a tactical covered call* strategy on individual stocks. DIVO is strategically designed to offer high levels of total return on a risk-adjusted basis.

Full DIVO Calculator →
📬

Get this IPSEF vs DIVO comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

IPSEF vs SCHDIPSEF vs JEPIIPSEF vs OIPSEF vs KOIPSEF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.